Recent Developments in Palliative Cancer Care

References

• Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics, and distress in a cancer popula-tion. Qual Life Res 1994; 3: 183–9.
   PubMed Web of Science ®Google Scholar
• Ingham JM, Portenoy RK. Symptom assessment. In: Cherny N, Foley K, eds. Pain and palliative care: hematol-ogy/oncology clinics of North America. Philadelphia: WB Saunders Company, 1996; 10: 21–39.
   Google Scholar
• Grossman SA, Sheidler VR, Sweden K, et al. Correlation of patient and caregiver ratings of cancer pain. J Pain Symp Manage 1991; 6: 53–7.
   PubMed Web of Science ®Google Scholar
• Price DD, MacGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as a ratio scale mea-surement for chronic and experimental pain. Pain 1983; 17: 45–56.
   PubMed Web of Science ®Google Scholar
• Bruera E, MacDonald S. Audit methods: the Edmonton Symptom Assessment System. In: Higginson I, ed. Clinical audit in palliative care. Oxford: Radcliffe Medical Press, 1993: 61–77.
   Google Scholar
• Higginson I. Audit methods: validation and in-patient use. In: Higginson I, ed. Clinical audit in palliative care. Oxford: Radcliffe Medical Press, 1993: 48–54.
   Google Scholar
• Fishman B, Pasternak S, Wallenstein SL, et al. The Memo-rial Pain Assessment Card. A valid instrument for the eval-uation of cancer pain. Cancer 1987; 60: 1151–8.
   Google Scholar
• Portenoy RK, Thaler HT, Kornblith AB, et al. The Memo-rial Symptom Assessment Scale. An instrument for the eval-uation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A: 1326–36.
   Google Scholar
• Graham C, Bond SS, Genkovich MM, et al. Use of the McGill Pain Questionnaire in the assessment of cancer pain: replicability and consistency. Pain 1980; 8: 377–87.
   PubMed Web of Science ®Google Scholar
• Dant RL, Cleeland CS, Flarery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 147–210.
   Google Scholar
• de Haes JCJM, van Kipperberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: struc-ture and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034.
   PubMedGoogle Scholar
• McCorkle R, Young K. Development of a symptom dis-tress scale. Cancer Nurs 1978; 1: 373–8.
   PubMedGoogle Scholar
• Au E, Loprinzi CL, Dhodapkar M, et al. Regular use of a verbal pain scale improves the understanding of oncology inpatient intensity. J Clin Oncol 1994; 12: 2751–5.
   PubMedGoogle Scholar
• Bruera E, Macmillan K, Hanson J, et al. Palliative care in a cancer centre: results in 1984 versus 1987. J Pain Symp Manage 1990; 5: 1–5.
   PubMedGoogle Scholar
• Bruera E, Schoeller T, Wenk R, et al. A prospective multi-center assessment of the Edmonton Staging System for can-cer pain. J Pain Symp Manage 1995; 10: 348–55.
   PubMed Web of Science ®Google Scholar
• Fainsinger R, Bruera E. Case report: is this opioid analgesic tolerance? J Pain Symp Manage 1995; 10: 573–7.
   PubMedGoogle Scholar
• Bruera E, Macmillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary re-port. Pain 1989; 37: 203–9.
   PubMed Web of Science ®Google Scholar
• Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997; 79: 835–42.
   Google Scholar
• Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J. Cognitive failure in patients with terminal can-cer: a prospective study. J Pain Symp Manage 1992; 7: 192–5.
   PubMed Web of Science ®Google Scholar
• Smith MJ, Breitbart WS, Platt MM. A critique of instru-ments and methods to detect, diagnose, and rate delirium. J Pain Symp Manage 1995; 10: 37–77.
   Google Scholar
• Katzman R, Brown T, Field P, et al. Validation of a short orientation-memory-concentration test of cognitive impair-ment. Am J Psychiatry 1983; 140: 734–9.
   PubMed Web of Science ®Google Scholar
• Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symp Manage 1997; 13: 128–37.
   PubMed Web of Science ®Google Scholar
• Moore RD, Bone LR, Geller G, et al. Prevalence, detection and treatment of alcoholism in hospitalized patients. J Am Med Assoc 1989; 261: 403–7.
   PubMed Web of Science ®Google Scholar
• Bruera E, Moyano J, Seifert L, Fainsinger RL, Hanson J, Suarez-Almazor M. The frequency of alcoholism among pa-tients with pain due to terminal cancer. J Pain Symp Man-age 1995; 10: 599–603.
   Google Scholar
• Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale; an examination of its reliability and validity in a research setting. Cancer 1984; 53: 2002–7.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. The European Organization for Research and Treatment of Cancer Study Group on Quality of Life-30. A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
   Google Scholar
• Kaasa T, Loomis J, Gillis K, et al. The Edmonton Functional Assessment Tool: preliminary development and evaluation for use in palliative care. J Pain Symp Manage 1997; 13: 10–9.
   PubMed Web of Science ®Google Scholar
• Bruera E, Suarez-Almazor M, Velasco A, Bertolino M, Mac-Donald SM, Hanson J. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symp Manage 1994; 9: 515–9.
   PubMed Web of Science ®Google Scholar
• Cohen SR, Mount BM, MacDonald N. Defining quality of life. Eur J Cancer 1996; 32A: 753–4.
   PubMedGoogle Scholar
• Cella DF, Tulsky DJ, Gray G, et al. The functional assess-ment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570–9.
   PubMed Web of Science ®Google Scholar
• Spitzer WU, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients; a concise QL-index for use by physicians. J Chronic DTS 1981; 34: 585–97.
   PubMedGoogle Scholar
• Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Ton K. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demon-strating the importance of the existential domain. Palliat Med 1997; 11: 3–20.
   PubMed Web of Science ®Google Scholar
• Foley K. The treatment of cancer pain. N Engl J Med 1985; 313: 84–95.
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Cancer pain-epidemiology and symptoms. Cancer 1989; 63: 2298–307.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer pain relief. 2nd ed. Geneva: World Health Organization, 1996.
   Google Scholar
• Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075–6.
   PubMed Web of Science ®Google Scholar
• Bruera E, Macmillan K, Hanson J, MacDonald RN. Pallia-tive care in a cancer center: results in 1984 vs 1987. J Pain Symp Manage 1990; 5: 1–5.
   PubMedGoogle Scholar
• de Lima L, Bruera E, Joranson DE, et al. From Florianopolis 1994 to Santo Domingo 1996: a progress report on opioid availability. Cancer Pain Release 1996; 9: 4–5.
   Google Scholar
• Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsy-chiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symp Manage 1995; 10: 131–41.
   PubMed Web of Science ®Google Scholar
• Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997; 79: 835–42.
   Google Scholar
• Levy MH. Pharmacologic treatment of cancer pain. New Engl J Med 1996; 335: 1124–32.
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Management of common opioid side effects during long term therapy of cancer pain. Ann Acad Med 1994; 23: 160–70.
   PubMedGoogle Scholar
• Bruera E, Miller MJ. Non-cardiogenic pulmonary edema after narcotic treatment for cancer pain. Pain 1989; 39: 297–300.
   PubMedGoogle Scholar
• Zacny JP, Lichtor JL, Thapar P, Coalson D, Flemming D, Thompson WK. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and mor-phine in healthy volunteers. J Pharmacol Exp Ther 1994; 270: 579–89.
   PubMed Web of Science ®Google Scholar
• Lipowski ZJ. Update on delirium. Psychiatr Clin N Am 1992; 15: 335–46.
   PubMed Web of Science ®Google Scholar
• Bruera E, Miller L, McCallion J, et al. Cognitive failure (CF) in patients with terminal cancer: a prospective study. J Pain Symp Manage 1992; 7: 192–5.
   PubMed Web of Science ®Google Scholar
• Ventafridda V, Ripamonti C, De Conno F, et al. Antidepres-sants increase bioavailability of morphine in cancer patients. Lancet 1987; 1: 1204.
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: influences on morphine and metabolite concen-tration. Clin Pharmacol Ther 1990; 48: 236–44.
   PubMed Web of Science ®Google Scholar
• Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992; 48: 397–9.
   Google Scholar
• Eisele JH, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 49: 231–2.
   Google Scholar
• Babul N, Darke AC. Putative role of hydromorphone metabolites in myoclonus. Pain 1993; 52: 123.
   Google Scholar
• MacDonald N, Der L, Allan S, et al. Opioid hyperexcitabil-ity: the application of alternate opioid therapy. Pain 1993; 53: 353–5.
   PubMed Web of Science ®Google Scholar
• Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977; 86: 738–41.
   PubMed Web of Science ®Google Scholar
• Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180–5.
   PubMed Web of Science ®Google Scholar
• Bowdle TA. Myoclonus following sufentanil without EEG seizure activity. Anesthesiology 1987; 67: 593–5.
   PubMed Web of Science ®Google Scholar
• de Stoutz ND, Tapper M, Fainsinger R. Reversible delirium in terminally ill patients. J Pain Symp Manage 1995; 10: 249–53.
   PubMed Web of Science ®Google Scholar
• Sjogren P, Jonsson T, Jensen N-H, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93–7.
   Google Scholar
• Sjogren P, Jensen N-H, Jensen T-S. Disappearance of mor-phine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59: 313–6.
   Google Scholar
• Sjogren P, Erikson J. Opioid toxicity. Curr Opin Anesthesiol 1994; 7: 465–9.
   Google Scholar
• Woolf CJ. Intrathecal high dose morphine produces hyperal-gesia in the rat. Brain Res 1981; 209: 491–5.
   PubMed Web of Science ®Google Scholar
• Yaksh TL, Harty GJ, Onofrio BM. High dose of spinal morphine produces a nonopiate receptor-mediated hyperes-thesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590–7.
   Google Scholar
• Gong QL, Hedner J, Björkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glu-curonide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249–55.
   Google Scholar
• Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259–74.
   Google Scholar
• Shohami E, Evron S. Intrathecal morphine induces myoclonic seizures in the rat. Acta Pharmacol Toxicol 1985; 56: 50–4.
   PubMedGoogle Scholar
• Mao J, Mayer DJ, Hayes RL, Price DD. Spatial patterns of increased spinal cord membrane-bound protein kinase C and their relation to increases in C-2-deoxyglucose metabolic ac-tivity in rats with painful peripheral mononeuropathy. J Neu-rophysiol 1993; 70: 470–81.
   Google Scholar
• Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-asparate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187: 165–8.
   Google Scholar
• Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996; 78: 852–7.
   Google Scholar
• Krames ES, Gershow Y, Glassberg A. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer 1985; 56: 696–702.
   Google Scholar
• Caraceni A, Martini C, De Conno F, et al. Organic brain syndromes and opioid administration for cancer pain. J Pain Symp Manage 1994; 9: 527–33.
   PubMed Web of Science ®Google Scholar
• Bruera E, Macmillan K, Kuehn N, Miller MJ. Circadian distribution of extra doses of narcotic analgesics in patientswith cancer pain. A preliminary report. Pain 1992; 49: 311–4.
   PubMed Web of Science ®Google Scholar
• Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke AC. Clinical efficacy and safety of a novel con-trolled release morphine suppository and subcutaneous mor-phine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13: 1520–7.
   PubMed Web of Science ®Google Scholar
• Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer pa-tients. J Pain Symp Manage 1994; 9: 298–302.
   PubMed Web of Science ®Google Scholar
• Bruera E, Watanabe S. Psychostimulants as adjuvant anal-gesics. J Pain Symp Manage 1994; 9: 412–5.
   PubMed Web of Science ®Google Scholar